文献速递神经核医学核素与放射性配体治疗

弥漫性内生性脑干胶质瘤的靶向放射性核素治疗:探索终点线之外的选择

Targeted Radionuclide Therapy in Diffuse Intrinsic Brainstem Gliomas: Exploring Options Beyond the Finish Line.
PubMed 文献 · Clin Nucl Med · 2025-06-09

本文报道一名12岁女孩于2022年7月诊断为弥漫性内生性脑干胶质瘤(DIPG),接受60 Gy/30次根治性放疗联合替莫唑胺后仍有残留病灶,转诊评估放射性诊疗可能性;68Ga-PSMA PET/CT显示脑桥肿块示踪剂摄取,随后接受2周期Lu-177 PSMA 617和1周期Ac-225 PSMA 617治疗。

要点

  • 儿童脑干胶质瘤约80%发生于脑桥,绝大多数脑桥肿瘤为DIPG,呈高级别、局部浸润性且预后差。
  • 12岁女孩DIPG放疗60 Gy/30次联合替莫唑胺后仍有残留病灶。
  • 68Ga-PSMA PET/CT示脑桥肿块示踪剂摄取,随后行2周期Lu-177 PSMA 617和1周期Ac-225 PSMA 617治疗。

核心结论

  • 本文报道一例DIPG患儿在放疗联合替莫唑胺后仍有残留病灶,经68Ga-PSMA PET/CT评估后接受Lu-177 PSMA 617和Ac-225 PSMA 617治疗。

研究设计与样本

  • 本文为病例报告,报道一名12岁女孩于2022年7月诊断为DIPG。

主要发现

  • 儿童脑干胶质瘤中约80%发生于脑桥,绝大多数脑桥肿瘤为DIPG,呈高级别、局部浸润性且预后差。
  • 患者接受60 Gy、30次、6周根治性放疗,随后接受替莫唑胺治疗。
  • 放疗联合替莫唑胺后仍有残留病灶,患者转诊至作者科室评估放射性诊疗可能性。
  • 68Ga-PSMA PET/CT显示脑桥肿块示踪剂摄取。
  • 患者随后接受2周期Lu-177 PSMA 617和1周期Ac-225 PSMA 617治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Of the pediatric brainstem gliomas, around 80% develop in the pons, with the vast majority of pontine tumors being diffuse intrinsic brainstem gliomas (DIPG), which tend to be high grade, locally infiltrative, and have a poor prognosis. We present a 12-year-old girl diagnosed with DIPG in July 2022, who received 60 Gy, 30 fractions of radical radiotherapy over 6 weeks, followed by temozolomide. With residual disease, the patient was referred to our department for the possibility of radiotheranostics. She underwent 68 Ga PSMA PET/CT, which revealed tracer accumulation in the pontine mass and was subsequently given 2 cycles of Lu-177 PSMA 617 and 1 cycle of Ac-225 PSMA 617 therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dharmashaktu Y, Tripathi M, Ballal S, et al. Targeted Radionuclide Therapy in Diffuse Intrinsic Brainstem Gliomas: Exploring Options Beyond the Finish Line. Clin Nucl Med. 2025. PMID: 40494369. doi:10.1097/RLU.0000000000005980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。